PERCEPTIVE ADVISORS LLC - 01 Aug 2025 Form 4 Insider Report for Orchestra BioMed Holdings, Inc. (OBIO)

Reporting relationship: 10%+ Owner
Issuer ticker: OBIO
Reported as of: 01 Aug 2025
Net transaction value: +$6,049,850
SEC form: 4
Accepted by SEC: 05 Aug 2025, 10:46:24 UTC
Prior SEC filing: 13 Jun 2025
Next SEC filing: 22 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Joseph Edelman - for Perceptive Advisors LLC, By: Joseph Edelman, its managing member

Key filing fact

PERCEPTIVE ADVISORS LLC filed Form 4 for Orchestra BioMed Holdings, Inc. (OBIO) on 05 Aug 2025.

Key facts

This page summarizes PERCEPTIVE ADVISORS LLC's Form 4 filing for Orchestra BioMed Holdings, Inc. (OBIO).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Aug 2025, 10:46.

Change

Previous filing in this sequence was filed on 13 Jun 2025.
Current net transaction value: +$6,049,850.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (3)

CIK 0001224962 Primary reporting owner

PERCEPTIVE ADVISORS LLC

Relationship: 10%+ Owner
Address: 51 ASTOR PLACE, 10TH FLOOR, NEW YORK
Signature: /s/ Joseph Edelman - for Perceptive Advisors LLC, By: Joseph Edelman, its managing member
Signature date: 05 Aug 2025

CIK 0001249675

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

Relationship: 10%+ Owner
Address: 51 ASTOR PLACE, 10TH FLOOR, NEW YORK
Signature: /s/ Joseph Edelman - for Perceptive Life Sciences Master Fund, Ltd., By: Perceptive Advisors LLC, its investment manager, By: Joseph Edelman, its managing member
Signature date: 05 Aug 2025

CIK 0001164426

EDELMAN JOSEPH

Relationship: 10%+ Owner
Address: 51 ASTOR PLACE, 10TH FLOOR, NEW YORK
Signature: /s/ Joseph Edelman
Signature date: 05 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OBIO transaction

Common Stock

Purchase

Transaction value: $1,925,000
Shares: +700,000
Change %: +15%
Price: $2.75
Shares after: 5,292,556
Date: 01 Aug 2025
Ownership: See Footnote
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OBIO transaction Derivative

Pre-funded Warrants (right to buy)

Purchase

Transaction value: $4,124,850
Shares: +1,500,000
Change %
Price: $2.75
Shares after: 1,500,000
Date: 01 Aug 2025
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 1,500,000
Exercise price: $0.000100
Footnotes: F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

PERCEPTIVE ADVISORS LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

Represents the purchase price for each share of Common Stock purchased by the Reporting Person in the Issuer's registered public offering that closed on August 1, 2025.

Footnote F2

The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of the Master Fund. Joseph Edelman ("Mr. Edelman") serves as the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of their indirect pecuniary interest therein, and this report shall not be deemed an admission that the Advisor or Mr. Edelman are beneficial owner of such securities for purposes of Section 16 or for any other purposes.

Footnote F3

The pre-funded warrants are immediately exercisable and will expire on the date they are exercised in full, subject to the Beneficial Ownership Limitation.

Footnote F4

Represents the purchase price for each pre-funded warrant purchased by the Reporting Person in the Issuer's registered public offering that closed on August 1, 2025.